In the rapidly growing longevity industry, companies are focusing on combatting sarcopenia, the age-related loss of muscle mass and strength. This has caught the attention of pharmaceutical companies and investors, not due to a newfound support for treating aging as a medical condition, but because of the need to counteract muscle loss caused by certain weight loss drugs. However, progress in developing effective treatments for sarcopenia has been limited, according to the SENS Research Foundation. The traditional approach of simply increasing muscle mass does not address the underlying cellular and molecular damage that contributes to muscle weakness in aging individuals. Instead, the focus should be on developing rejuvenation biotechnologies that can repair this damage and restore muscle function. For more information, visit the SENS Research Foundation website. Link: https://www.sens.org/legs-of-iron-feet-of-clay/